Mersana Therapeutics, an early-stage biotech developing antibody drug conjugate therapies for cancers, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Mersana Therapeutics plans to list on the Nasdaq under the symbol MRSN. J.P. Morgan, Cowen & Company and Leerink Partners acted as lead managers on the deal.
